Cargando…
Scenario drafting to anticipate future developments in technology assessment
BACKGROUND: Health Technology Assessment (HTA) information, and in particular cost-effectiveness data is needed to guide decisions, preferably already in early stages of technological development. However, at that moment there is usually a high degree of uncertainty, because evidence is limited and...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444406/ https://www.ncbi.nlm.nih.gov/pubmed/22894140 http://dx.doi.org/10.1186/1756-0500-5-442 |
_version_ | 1782243679243599872 |
---|---|
author | Retèl, Valesca P Joore, Manuela A Linn, Sabine C Rutgers, Emiel JT van Harten, Wim H |
author_facet | Retèl, Valesca P Joore, Manuela A Linn, Sabine C Rutgers, Emiel JT van Harten, Wim H |
author_sort | Retèl, Valesca P |
collection | PubMed |
description | BACKGROUND: Health Technology Assessment (HTA) information, and in particular cost-effectiveness data is needed to guide decisions, preferably already in early stages of technological development. However, at that moment there is usually a high degree of uncertainty, because evidence is limited and different development paths are still possible. We developed a multi-parameter framework to assess dynamic aspects of a technology -still in development-, by means of scenario drafting to determine the effects, costs and cost-effectiveness of possible future diffusion patterns. Secondly, we explored the value of this method on the case of the clinical implementation of the 70-gene signature for breast cancer, a gene expression profile for selecting patients who will benefit most from chemotherapy. METHODS: To incorporate process-uncertainty, ten possible scenarios regarding the introduction of the 70-gene signature were drafted with European experts. Out of 5 most likely scenarios, 3 drivers of diffusion (non-compliance, technical failure, and uptake) were quantitatively integrated in a decision-analytical model. For these scenarios, the cost-effectiveness of the 70-gene signature expressed in Incremental Cost-Effectiveness Ratios (ICERs) was compared to clinical guidelines, calculated from the past (2005) until the future (2020). RESULTS: In 2005 the ICER was €1,9 million/quality-adjusted-life-year (QALY), meaning that the 70-gene signature was not yet cost-effective compared to the current clinical guideline. The ICER for the 70-gene signature improved over time with a range of €1,9 million to €26,145 in 2010 and €1,9 million to €11,123/QALY in 2020 depending on the separate scenario used. From 2010, the 70-gene signature should be cost-effective, based on the combined scenario. The uptake-scenario had strongest influence on the cost-effectiveness. CONCLUSIONS: When optimal diffusion of a technology is sought, incorporating process-uncertainty by means of scenario drafting into a decision model may reveal unanticipated developments and can demonstrate a range of possible cost-effectiveness outcomes. The effect of scenarios give additional information on the speed with cost effectiveness might be reached and thus provide a more realistic picture for policy makers, opinion leaders and manufacturers. |
format | Online Article Text |
id | pubmed-3444406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34444062012-09-20 Scenario drafting to anticipate future developments in technology assessment Retèl, Valesca P Joore, Manuela A Linn, Sabine C Rutgers, Emiel JT van Harten, Wim H BMC Res Notes Research Article BACKGROUND: Health Technology Assessment (HTA) information, and in particular cost-effectiveness data is needed to guide decisions, preferably already in early stages of technological development. However, at that moment there is usually a high degree of uncertainty, because evidence is limited and different development paths are still possible. We developed a multi-parameter framework to assess dynamic aspects of a technology -still in development-, by means of scenario drafting to determine the effects, costs and cost-effectiveness of possible future diffusion patterns. Secondly, we explored the value of this method on the case of the clinical implementation of the 70-gene signature for breast cancer, a gene expression profile for selecting patients who will benefit most from chemotherapy. METHODS: To incorporate process-uncertainty, ten possible scenarios regarding the introduction of the 70-gene signature were drafted with European experts. Out of 5 most likely scenarios, 3 drivers of diffusion (non-compliance, technical failure, and uptake) were quantitatively integrated in a decision-analytical model. For these scenarios, the cost-effectiveness of the 70-gene signature expressed in Incremental Cost-Effectiveness Ratios (ICERs) was compared to clinical guidelines, calculated from the past (2005) until the future (2020). RESULTS: In 2005 the ICER was €1,9 million/quality-adjusted-life-year (QALY), meaning that the 70-gene signature was not yet cost-effective compared to the current clinical guideline. The ICER for the 70-gene signature improved over time with a range of €1,9 million to €26,145 in 2010 and €1,9 million to €11,123/QALY in 2020 depending on the separate scenario used. From 2010, the 70-gene signature should be cost-effective, based on the combined scenario. The uptake-scenario had strongest influence on the cost-effectiveness. CONCLUSIONS: When optimal diffusion of a technology is sought, incorporating process-uncertainty by means of scenario drafting into a decision model may reveal unanticipated developments and can demonstrate a range of possible cost-effectiveness outcomes. The effect of scenarios give additional information on the speed with cost effectiveness might be reached and thus provide a more realistic picture for policy makers, opinion leaders and manufacturers. BioMed Central 2012-08-16 /pmc/articles/PMC3444406/ /pubmed/22894140 http://dx.doi.org/10.1186/1756-0500-5-442 Text en Copyright ©2012 Retèl et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Retèl, Valesca P Joore, Manuela A Linn, Sabine C Rutgers, Emiel JT van Harten, Wim H Scenario drafting to anticipate future developments in technology assessment |
title | Scenario drafting to anticipate future developments in technology assessment |
title_full | Scenario drafting to anticipate future developments in technology assessment |
title_fullStr | Scenario drafting to anticipate future developments in technology assessment |
title_full_unstemmed | Scenario drafting to anticipate future developments in technology assessment |
title_short | Scenario drafting to anticipate future developments in technology assessment |
title_sort | scenario drafting to anticipate future developments in technology assessment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3444406/ https://www.ncbi.nlm.nih.gov/pubmed/22894140 http://dx.doi.org/10.1186/1756-0500-5-442 |
work_keys_str_mv | AT retelvalescap scenariodraftingtoanticipatefuturedevelopmentsintechnologyassessment AT jooremanuelaa scenariodraftingtoanticipatefuturedevelopmentsintechnologyassessment AT linnsabinec scenariodraftingtoanticipatefuturedevelopmentsintechnologyassessment AT rutgersemieljt scenariodraftingtoanticipatefuturedevelopmentsintechnologyassessment AT vanhartenwimh scenariodraftingtoanticipatefuturedevelopmentsintechnologyassessment |